Compile Data Set for Download or QSAR
Report error Found 138 Enz. Inhib. hit(s) with all data for entry = 12385
TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699755(US20240335420, Compound 40)
Affinity DataIC50: 123nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699756(US20240335420, Compound 54)
Affinity DataIC50: 137nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699755(US20240335420, Compound 40)
Affinity DataIC50: 140nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699761(US20240335420, Compound 64)
Affinity DataIC50: 173nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699758(US20240335420, Compound 61)
Affinity DataIC50: 183nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699751(US20240335420, Compound 31)
Affinity DataIC50: 224nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699750(US20240335420, Compound 15)
Affinity DataIC50: 272nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699750(US20240335420, Compound 15)
Affinity DataIC50: 297nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699759(US20240335420, Compound 62)
Affinity DataIC50: 302nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699760(US20240335420, Compound 63)
Affinity DataIC50: 306nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699756(US20240335420, Compound 54)
Affinity DataIC50: 313nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699707(US20240335420, Compound 10)
Affinity DataIC50: 362nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699761(US20240335420, Compound 64)
Affinity DataIC50: 384nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699751(US20240335420, Compound 31)
Affinity DataIC50: 444nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699759(US20240335420, Compound 62)
Affinity DataIC50: 462nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699763(US20240335420, Compound 66)
Affinity DataIC50: 569nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699764(US20240335420, Compound 68)
Affinity DataIC50: 636nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699758(US20240335420, Compound 61)
Affinity DataIC50: 651nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699749(US20240335420, Compound 14)
Affinity DataIC50: 754nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699752(US20240335420, Compound 38)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699753(US20240335420, Compound 39)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699754(US20240335420, Compound 41)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699760(US20240335420, Compound 63)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699762(US20240335420, Compound 65)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699763(US20240335420, Compound 66)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699765(US20240335420, Compound 69)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699766(US20240335420, Compound 71)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699767(US20240335420, Compound 72)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699768(US20240335420, Compound 73)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699769(US20240335420, Compound 74)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699770(US20240335420, Compound 75)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699771(US20240335420, Compound 76)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699723(US20240335420, Compound 32)
Affinity DataIC50: 1.05E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699754(US20240335420, Compound 41)
Affinity DataIC50: 1.20E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699749(US20240335420, Compound 14)
Affinity DataIC50: 1.32E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699723(US20240335420, Compound 32)
Affinity DataIC50: 1.36E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699707(US20240335420, Compound 10)
Affinity DataIC50: 1.37E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699709(US20240335420, Compound 12)
Affinity DataIC50: 1.89E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699709(US20240335420, Compound 12)
Affinity DataIC50: 3.21E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699718(US20240335420, Compound 26)
Affinity DataIC50: 3.50E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699710(US20240335420, Compound 16)
Affinity DataIC50: 4.12E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699710(US20240335420, Compound 16)
Affinity DataIC50: 4.25E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699757(US20240335420, Compound 60)
Affinity DataIC50: 5.04E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699757(US20240335420, Compound 60)
Affinity DataIC50: 5.15E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699713(US20240335420, Compound 19)
Affinity DataIC50: 5.72E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699716(US20240335420, Compound 24)
Affinity DataIC50: 5.72E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699713(US20240335420, Compound 19)
Affinity DataIC50: 5.90E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699716(US20240335420, Compound 24)
Affinity DataIC50: 5.90E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699706(US20240335420, Compound 7)
Affinity DataIC50: 6.27E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699762(US20240335420, Compound 65)
Affinity DataIC50: 6.44E+3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 138 total ) | Next | Last >>
Jump to: